← Back to Dashboard

Jeremy Friese, MD

highactive
founderphysicianprior-authinvestor406-ventures-portfolio

Call History

1
2025-12-08Jeremy Friese — Dec 8, 2025

Jeremy Friese — Dec 8, 2025

Attendees: Thomas, Michael, Jeremy Duration: 30 min How we connected: Brad Fluegel (Wharton professor) introduced us.


Jeremy's Opening Frame

  • "It's a big enough problem. We need more people jumping in to solve it. I have zero concerns of competitive challenges."
  • AI adoption in healthcare is 2x faster than any other industry, driven by: (1) ambient dictation/AI scribes, (2) back-office — coding, prior auth, medical necessity, concurrent review
  • Key insight: concurrent review, prior auth, and medical necessity are all the same problem with different niches. Same tech deployment, different applications. Tells us to frame it that way for investors: "We're starting in concurrent review. It's the same problem as PA and medical necessity. We'll expand."

MCG / InterQual Warning (CRITICAL)

  • Their moat is "a bunch of really high paid lawyers." MCG especially is litigious.
  • They care more about payer customers than provider customers → provider side may be safer to start
  • DaisyAI is already on their radar after approaching InterQual (they brought a lawyer to a student call)
  • "5 billion incentives to make sure you are not successful"
  • Don't be sneaky. "They will know. It will either be so tied up you can't raise money, or it will kill your company."
  • Not about ethics — "anybody can sue for anything" — it's about not catching their eye
  • Iodine precedent: Took first-principles approach on CDI (similar to our approach). "Worked until $100M, then went completely flat and started going down."

Strategic Advice

  • Start unsexy. Workers comp is interesting — sizable market, MCG/InterQual don't care about it. Legal profession angle also worth considering.
  • Don't think about scalable sales process yet. Build trust, understand one person's problem, build for them. Just make sure their problem is the same as 10 others' (don't build a one-off).
  • Tandem example: $1B business selling to tiny clinics. Serve a market segment others ignore.
  • Get a clinical person on the team ASAP. Healthcare buyers are skeptical of non-healthcare people. Borrow credibility. "Between Doctor Joe and I, we've done 10,000." Find a nurse with sales instincts — most don't have it.
  • Don't raise until you have to. "Once you raise money the clock is ticking." Get as far as you can with bootstrap + first contracts.

On Concurrent Review

  • Jeremy has always planned to expand Humata into concurrent review but hasn't — "it's a quagmire" with MCG/InterQual dynamics
  • Prior auth keeps exploding so he hasn't needed to
  • Every single health system customer asks him for concurrent review help. "No doubt there's a need. You just got to thread the needle."

Relationship Signal

  • Extremely generous, zero territorial instinct
  • "I exist to solve this problem and I can't do it alone"
  • "Please keep me posted. I would love to be on your list of folks to talk to."
  • HBS/Wharton banter — good energy

Current Roles

  • Humata Health — Founder/CEO. Prior auth platform, both provider and payer side. CMS WISeR pilot partner. Raised $25M from Blue Venture Fund, LRVHealth, Optum Ventures, .406 Ventures, Highmark Health Ventures.
  • The Donna Fund — Founder. Invests in female founders in healthcare/tech. Named after his mother who died of breast cancer.
  • Health Evolution Fellow
  • Mayo Clinic — Venture Partner Advisor
  • Angel investor in Here Now Health, FamilyWell Health, Rezilient Health, Tuesday Health, BASILISK
  • CHAI — leads Prior Authorization Workgroup

Career Arc

  • Mayo Clinic radiologist (19 years) → healthcare biz dev executive
  • Co-founded Evidentia Health (Mayo + UMN joint venture, smart radiology reports)
  • Co-founded Verata Health ("frictionless prior authorization") → acquired by Olive AI (Dec 2020). Backed by BCBS Venture Fund, Bessemer, LRVHealth.
  • President, Payer at Olive (2020–2022)
  • Career break → founded Humata Health (2023)

Interactions

DateTypeNotes
Dec 8, 2025Intro call30-min call via Brad Fluegel intro. Very generous with time and advice. Full notes

Notes

  • His tagline: "Mayo Clinic Doc Solving Prior Auth" — he brands around the mission, not the company
  • Personal: mom died of stage 4 breast cancer at 50, it drove him to medicine. Very mission-driven.
  • Humata's WISeR pilot showing 99% provider satisfaction in first week — real traction
  • .406 Ventures invested in Humata → .406 knows and trusts Jeremy → Jeremy could intro us to .406 with credibility
  • Brad Fluegel is the connector — worth noting in Brad's file if we create one

Who

  • Mayo Clinic radiologist turned serial healthcare founder
  • Founder/Chairman/CEO of Humata Health — prior authorization platform backed by 40+ hospitals, BCBS, Optum/UHG. Chosen by CMS as primary tech partner for the WISeR prior auth pilot in Oklahoma.
  • Harvard Business School MBA (co-authored case study with Michael Porter, edited Clay Christensen's "The Innovator's Prescription")
  • Mayo Clinic MD, 19 years there including Senior Medical Director for Global Business Development
  • Based in Wilson, Wyoming
  • 11,400+ LinkedIn followers — real thought leader in the space

Connection to Us

  • Introduced via Brad Fluegel (Wharton professor)
  • Mutual connections: Justin Silver, David Vignes + 2 others
  • Very open from the start: "It's a big enough problem. We need more people jumping in. I have zero concerns of competitive challenges."
  • Explicitly offered to be an ongoing resource: "I would love to be on your list of folks to talk to."
  • Critical: Humata Health is a .406 Ventures portfolio company ($25M round). Thomas just cold-emailed .406 — Jeremy is the warm path in.

Why He Matters

  • He's building the prior auth equivalent of what DaisyAI is building for utilization management. Adjacent, not competitive — but deeply overlapping ecosystem.
  • Knows every investor, health system exec, and payer in this space
  • .406 Ventures portfolio company — direct warm path to the fund Thomas is trying to reach
  • Has the CMS relationship (WISeR pilot) — policy-level credibility
  • Active angel investor — could invest directly or connect us to his network
  • Thought leader: publishes on PA regulation, interoperability, healthcare AI

Activity

Total calls1
Last call2025-12-08
First call2025-12-08

Daisy

v1

What do you need?

I can pull up the fundraise pipeline, CRM accounts, hot board, meeting notes — anything in the OS.

Sonnet · read-only